Jaguar Health (NASDAQ:JAGX) reported quarterly losses of $(6.28) per share which missed the analyst consensus estimate of $(5.08) by 23.62 percent. This is a 76.08 percent increase over losses of $(26.25) per share from the same period last year. The company reported quarterly sales of $3.083 million which missed the analyst consensus estimate of $3.730 million by 17.35 percent. This is a 0.84 percent decrease over sales of $3.109 million the same period last year.